- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06232707
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Buenos Aires
-
Florencio Varela, Buenos Aires, Argentina, 1888
- Local Institution - 0222
-
La Plata, Buenos Aires, Argentina, 1900
- Local Institution - 0001
-
Pilar, Buenos Aires, Argentina, 1629
- Local Institution - 0262
-
-
Ciudad Autónoma De Buenos Aires
-
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina, C1118AAT
- Local Institution - 0002
-
-
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Local Institution - 0260
-
Macquarie University, New South Wales, Australia, 2109
- Local Institution - 0246
-
Waratah, New South Wales, Australia, 2298
- Local Institution - 0022
-
-
Queensland
-
Brisbane, Queensland, Australia, 4120
- Local Institution - 0397
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Local Institution - 0021
-
Clayton, Victoria, Australia, 3168
- Local Institution - 0019
-
Melbourne, Victoria, Australia, 3004
- Local Institution - 0018
-
Melbourne, Victoria, Australia, 3065
- Local Institution - 0003
-
-
-
-
-
Salzburg, Austria, 5020
- Local Institution - 0334
-
Wien, Austria, 1090
- Local Institution - 0332
-
-
Niederösterreich
-
St. Polten, Niederösterreich, Austria, 3100
- Local Institution - 0333
-
-
Tirol
-
Innsbruck, Tirol, Austria, 6020
- Local Institution - 0337
-
-
-
-
Antwerpen
-
Brasschaat, Antwerpen, Belgium, 2930
- Local Institution - 0284
-
-
Liège
-
Verviers, Liège, Belgium, 4800
- Local Institution - 0280
-
-
Namur
-
Yvoir, Namur, Belgium, 5530
- Local Institution - 0279
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- Local Institution - 0286
-
-
-
-
-
Rio de Janeiro, Brazil, 22250-905
- Local Institution - 0291
-
São Paulo, Brazil, 05652-900
- Local Institution - 0211
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30110-022
- Local Institution - 0274
-
-
Rio Grande Do Norte
-
Natal, Rio Grande Do Norte, Brazil, 59025050
- Local Institution - 0351
-
-
São Paulo
-
Sao Paulo, São Paulo, Brazil, 01509-010
- Local Institution - 0369
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Local Institution - 0417
-
Edmonton, Alberta, Canada, T6G1Z2
- Local Institution - 0423
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Local Institution - 0402
-
Toronto, Ontario, Canada, M5G 2M9
- Local Institution - 0395
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Local Institution - 0031
-
Montréal, Quebec, Canada, H2X 1P1
- Local Institution - 0098
-
-
-
-
Metropolitana DE Santiago
-
Santiago, Metropolitana DE Santiago, Chile, 7580206
- Local Institution - 0027
-
-
Región Metropolitana De Santiago
-
Santiago, Región Metropolitana De Santiago, Chile, 7500921
- Local Institution - 0030
-
Santiago, Región Metropolitana De Santiago, Chile, 7650568
- Local Institution - 0029
-
Santiago, Región Metropolitana De Santiago, Chile, 7620002
- Local Institution - 0026
-
-
-
-
-
Qingdao, China, 266011
- Local Institution - 0367
-
-
Beijing
-
Beijing, Beijing, China
- Local Institution - 0413
-
Beijing, Beijing, China, 100020
- Local Institution - 0230
-
Beijing, Beijing, China, 100034
- Local Institution - 0040
-
Changping, Beijing, China, 102200
- Local Institution - 0366
-
-
Chongqing
-
Chongqing, Chongqing, China, 400016
- Local Institution - 0057
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Local Institution - 0080
-
Guangzhou, Guangdong, China, 510060
- Local Institution - 0066
-
Guangzhou, Guangdong, China, 510515
- Local Institution - 0226
-
Shenzhen, Guangdong, China, 518036
- Local Institution - 0368
-
-
Hebei
-
Baoding, Hebei, China, 071030
- Local Institution - 0365
-
Shijiazhuang, Hebei, China, 050051
- Local Institution - 0082
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Local Institution - 0041
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Local Institution - 0075
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Local Institution - 0062
-
Changsha, Hunan, China, 410013
- Local Institution - 0053
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Local Institution - 0055
-
Suzhou, Jiangsu, China, 215006
- Local Institution - 0067
-
Xuzhou, Jiangsu, China, 221006
- Local Institution - 0377
-
-
Liaoning
-
Shenyang, Liaoning, China, 110004
- Local Institution - 0044
-
-
Shaanxi
-
Xi'An, Shaanxi, China, 710004
- Local Institution - 0072
-
-
Shandong
-
Jinan, Shandong, China, 250014
- Local Institution - 0077
-
Jinan, Shandong, China, 250117
- Local Institution - 0083
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Local Institution - 0273
-
Shanghai, Shanghai, China, 200081
- Local Institution - 0421
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030000
- Local Institution - 0245
-
-
Tianjin
-
Tianjin, Tianjin, China, 300052
- Local Institution - 0056
-
Tianjin, Tianjin, China, 300308
- Local Institution - 0422
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Local Institution - 0070
-
Hangzhou, Zhejiang, China, 310003
- Local Institution - 0203
-
-
-
-
-
Praha 2, Czechia, 12808
- Local Institution - 0012
-
-
Brno-město
-
Brno, Brno-město, Czechia, 625 00
- Local Institution - 0013
-
-
Olomoucký Kraj
-
Olomouc, Olomoucký Kraj, Czechia, 779 00
- Local Institution - 0247
-
-
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, France, 31100
- Local Institution - 0118
-
-
Languedoc-Roussillon
-
Montpellier, Languedoc-Roussillon, France, 34295
- Local Institution - 0225
-
-
Lorraine
-
Vandoeuvre lès Nancy, Lorraine, France, 54511
- Local Institution - 0224
-
-
Nord
-
Lille, Nord, France, 59000
- Local Institution - 0084
-
-
Pays-de-la-Loire
-
Nantes, Pays-de-la-Loire, France, 44000
- Local Institution - 0085
-
-
Rhône
-
Pierre-Bénite, Rhône, France, 69310
- Local Institution - 0192
-
-
-
-
-
Hamburg, Germany, 22763
- Local Institution - 0339
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69120
- Local Institution - 0331
-
Tübingen, Baden-Württemberg, Germany, 72076
- Local Institution - 0330
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
- Local Institution - 0335
-
Leipzig, Sachsen, Germany, 04103
- Local Institution - 0329
-
-
-
-
Attikí
-
Athens, Attikí, Greece, 115 28
- Local Institution - 0004
-
Chaidari, Attikí, Greece, 12462
- Local Institution - 0136
-
-
-
-
-
Budapest, Hungary, 1088
- Local Institution - 0104
-
Budapest, Hungary, 1097
- Local Institution - 0105
-
-
Szabolcs-Szatmár-Bereg
-
Nyiregyhaza, Szabolcs-Szatmár-Bereg, Hungary, 4400
- Local Institution - 0103
-
-
Vas
-
Szombathely, Vas, Hungary, 9700
- Local Institution - 0108
-
-
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, India, 530040
- Local Institution - 0370
-
-
Haryana
-
Gurugram, Haryana, India, 122011
- Local Institution - 0362
-
-
Karnataka
-
Bangalore, Karnataka, India, 560092
- Local Institution - 0403
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226014
- Local Institution - 0399
-
-
West Bengal
-
Kolkata, West Bengal, India, 700094
- Local Institution - 0398
-
-
-
-
-
Cork, Ireland, T12 E8YV
- Local Institution - 0281
-
Dublin, Ireland, D04 N2E0
- Local Institution - 0371
-
Dublin, Ireland, D08 E9P6
- Local Institution - 0285
-
Limerick, Ireland, V94 F858
- Local Institution - 0269
-
-
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italy, 47014
- Local Institution - 0096
-
-
Milano
-
Legnano, Milano, Italy, 20025
- Local Institution - 0294
-
Milan, Milano, Italy, 20162
- Local Institution - 0265
-
-
Sicilia
-
Palermo, Sicilia, Italy, 90127
- Local Institution - 0410
-
-
-
-
-
Aomori, Japan, 030-8553
- Local Institution - 0419
-
Chiba, Japan, 260-8677
- Local Institution - 0383
-
Kumamoto, Japan, 860-8556
- Local Institution - 0391
-
Kyoto, Japan, 602-8566
- Local Institution - 0389
-
Okayama, Japan, 701-1192
- Local Institution - 0388
-
Tokyo, Japan, 150-8935
- Local Institution - 0384
-
-
Aichi
-
Anjo, Aichi, Japan, 446-8602
- Local Institution - 0409
-
Nagoya, Aichi, Japan, 467-8602
- Local Institution - 0387
-
-
Chiba
-
Kamogawa, Chiba, Japan, 296-0041
- Local Institution - 0407
-
Kashiwa, Chiba, Japan, 277-8577
- Local Institution - 0385
-
-
Kanagawa
-
Isehara, Kanagawa, Japan, 259-1193
- Local Institution - 0386
-
-
Osaka
-
Osaka-sayama, Osaka, Japan, 589-8511
- Local Institution - 0390
-
-
Tochigi
-
Shimotsuga, Tochigi, Japan, 321-0293
- Local Institution - 0381
-
-
Tokyo
-
Koto, Tokyo, Japan, 135-8550
- Local Institution - 0382
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Korea, Republic of, 13620
- Local Institution - 0240
-
-
Pusan-Kwangyǒkshi
-
Busan, Pusan-Kwangyǒkshi, Korea, Republic of, 49201
- Local Institution - 0221
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of, 03080
- Local Institution - 0036
-
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of, 05505
- Local Institution - 0239
-
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of, 06351
- Local Institution - 0034
-
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of, 06591
- Local Institution - 0035
-
-
-
-
-
Oslo, Norway, 0450
- Local Institution - 0193
-
-
Akershus
-
Løenskog, Akershus, Norway, 1474
- Local Institution - 0137
-
-
Hordaland
-
Bergen, Hordaland, Norway, 5021
- Local Institution - 0115
-
-
-
-
-
Lisboa, Portugal, 1500-650
- Local Institution - 0255
-
-
Lisboa
-
Lisbon, Lisboa, Portugal, 1099-023
- Local Institution - 0242
-
Lisbon, Lisboa, Portugal, 1649-035
- Local Institution - 0415
-
-
-
-
-
Brasov, Romania, 500052
- Local Institution - 0171
-
București, Romania, 050098
- Local Institution - 0414
-
-
București
-
Bucuresti, București, Romania, 022328
- Local Institution - 0169
-
-
-
-
-
Jerez de la Frontera, Spain, 11407
- Local Institution - 0202
-
Salamanca, Spain, 37007
- Local Institution - 0006
-
Santiago de Compostela, Spain, 15706
- Local Institution - 0007
-
València, Spain, 46026
- Local Institution - 0009
-
-
Barcelona [Barcelona]
-
Badalona, Barcelona [Barcelona], Spain, 08916
- Local Institution - 0011
-
-
Murcia, Región De
-
El Palmar, Murcia, Murcia, Región De, Spain, 30120
- Local Institution - 0234
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Local Institution - 0008
-
-
-
-
Västra Götalands Län [se-14]
-
Borås, Västra Götalands Län [se-14], Sweden, 501 82
- Local Institution - 0114
-
Gothenburg, Västra Götalands Län [se-14], Sweden, 413 45
- Local Institution - 0111
-
-
-
-
-
Zürich, Switzerland, 8063
- Local Institution - 0338
-
-
Berne
-
Bern, Berne, Switzerland, 3010
- Local Institution - 0336
-
-
Sankt Gallen
-
st.Gallen, Sankt Gallen, Switzerland, 9007
- Local Institution - 0411
-
-
-
-
-
Ankara, Turkey, 06200
- Local Institution - 0375
-
Kayseri, Turkey
- Local Institution - 0187
-
İzmir, Turkey, 35100
- Local Institution - 0188
-
-
İstanbul
-
Stanbul, İstanbul, Turkey, 34214
- Local Institution - 0325
-
-
-
-
-
Cardiff, United Kingdom, CF14 4XW
- Local Institution - 0350
-
Derby, United Kingdom, DE22 3NE
- Local Institution - 0344
-
Manchester, United Kingdom, M20 4BX
- Local Institution - 0343
-
-
Hampshire
-
Southampton, Hampshire, United Kingdom, SO16 0YD
- Local Institution - 0349
-
-
London, City Of
-
London, London, City Of, United Kingdom, NW1 2PG
- Local Institution - 0342
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Local Institution - 0151
-
-
California
-
Los Angeles, California, United States, 90095
- Local Institution - 0088
-
Stanford, California, United States, 94305
- Local Institution - 0358
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Local Institution - 0355
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Local Institution - 0434
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Local Institution - 0433
-
-
Kentucky
-
Saint Matthews, Kentucky, United States, 40207
- Local Institution - 0439
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Local Institution - 0323
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Local Institution - 0324
-
Bethesda, Maryland, United States, 20889
- Local Institution - 0441
-
-
Montana
-
Billings, Montana, United States, 59102
- Local Institution - 0435
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Local Institution - 0157
-
Summit, New Jersey, United States, 07901
- Local Institution - 0359
-
-
New York
-
Lake Success, New York, United States, 11042
- Local Institution - 0430
-
New York, New York, United States, 10065
- Local Institution - 0396
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- Local Institution - 0306
-
Cleveland, Ohio, United States, 44109
- Local Institution - 0199
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Local Institution - 0437
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Local Institution - 0352
-
-
South Dakota
-
Watertown, South Dakota, United States, 57201
- Local Institution - 0420
-
-
Texas
-
Dallas, Texas, United States, 75390-88520
- Local Institution - 0168
-
-
Washington
-
Seattle, Washington, United States, 98109
- Local Institution - 0405
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Participant is willing and able to adhere to the study visit schedule and other protocol requirements including bone marrow aspirations and/or biopsies and hospitalization during the first cycle.
Documented diagnosis of multiple myeloma (MM), and must:.
i) Received at least 1 but not more than 3 prior lines of anti-myeloma therapy.
ii) Received prior treatment with lenalidomide and an anti-CD38 monoclonal antibody (for at least 2 consecutive cycles).
iii) Achieved minimal response (MR) or better to at least 1 prior anti-myeloma therapy.
iv) Documented PD during or after their last anti-myeloma therapy or failure to achieve response.
- Must have measurable disease (as determined by central laboratory).
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at the time of the screening.
Exclusion Criteria
- Active, uncontrolled, or suspected infection.
- Known current, or history of, central nervous system involvement of multiple myeloma.
- History or presence of clinically relevant CNS pathology.
- Received prior BCMA-targeted TCE or BCMA-targeted CAR-T therapy.
- Previously received allogeneic stem cell transplantation at any time or received autologous stem cell transplantation within 3 months of initiating study intervention.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm A: Alnuctamab
|
Specified dose on specified days
Other Names:
|
|
Active Comparator: Arm B: Standard of Care Regimens
|
Specified dose on specified days
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free Survival (PFS)
Time Frame: Up to 5 years
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to response (TTR)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Duration of response (DOR)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Overall Survival (OS)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Incidence of serious adverse events (SAEs)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Overall response (OR)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Complete response (CR) or better
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Very good partial response (VGPR) or better
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Time to progression (TTP)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Time to next treatment (TTNT)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Progression-free survival 2 (PFS2)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Restricted mean DOR (RMDOR)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Minimal residual disease (MRD) negativity rate
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Incidence of adverse events (AEs)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Change from baseline in subscale scores of European organization for research and treatment of cancer - quality of life core 30 (EORTC QLQ-C30)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Change from baseline in subscale scores of European quality of life multiple myeloma module (EORTC QLQ-MY20)
Time Frame: Up to 5 years
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Pomalidomide
- Daratumumab
- Antibodies, Monoclonal
- Elotuzumab
Other Study ID Numbers
- CA058-1019
- 2023-509472-42 (Registry Identifier: EU Trial Number)
- U1111-1281-8227 (Registry Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at:
https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Zhongshan Hospital (Xiamen), Fudan UniversityNot yet recruitingMultiple Myeloma Progression | Multiple Myeloma Refractory
-
University Health Network, TorontoNot yet recruitingMultiple Myeloma in Relapse | Multiple Myeloma RefractoryCanada
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
PETHEMA FoundationNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Tongji Hospital; Jinhua Municipal Central Hospital; Taizhou Hospital of Zhejiang...RecruitingRelapse Multiple MyelomaChina
-
Guangzhou Bio-gene Technology Co., LtdWithdrawnMultiple Myeloma Refractory
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Dexamethasone
-
Poznan University of Medical SciencesRecruitingHip Pain Chronic | Hip OsteoarthritisPoland
-
Beijing Tiantan HospitalBeijing Ditan Hospital; Beijing Electric Power HospitalNot yet recruiting
-
Poznan University of Medical SciencesNot yet recruitingOsteoarthritis, Hip | Hip OsteoarthritisPoland
-
TheiaNova Ltd.Enrolling by invitation
-
Woman'sRecruitingOral Mucositis Due to ChemotherapyUnited States
-
Shandong UniversityRecruitingPrimary Immune Thrombocytopenia (ITP)China
-
Semnur Pharmaceuticals, Inc.Cromos Pharma LLC; SyngeneNot yet recruitingLumbosacral Radicular Pain
-
Eye & ENT Hospital of Fudan UniversityShanghai Zhongshan Hospital; Shenzhen Second People's HospitalNot yet recruiting
-
Sheffield Children's NHS Foundation TrustRecruitingDexamethasone | Acute AsthmaUnited Kingdom
-
Second Affiliated Hospital, School of Medicine,...West China Hospital; Ningbo Medical Center Lihuili Hospital; Jinhua People's... and other collaboratorsRecruitingInflammatory Bowel Disease (IBD) | UC - Ulcerative Colitis | CD - Crohn's DiseaseChina